Drug intelligence / Profile preview

AL014

Development stage: Discontinued
Lead developer: Alector
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**AL014** is an investigational **monoclonal antibody** developed by **Alector** for **Alzheimer's disease**. Public company materials describe it as targeting **MS4A4A**, a microglia-associated transmembrane protein in the MS4A locus linked to Alzheimer's disease genetic risk, with the intended goal of modulating microglial biology in a therapeutically beneficial direction. Available pipeline and drug-database sources indicate the program was in preclinical development and is now **discontinued**, with no evidence of marketing approval or an established commercial product identity.

Targets

MS4A4A (Membrane-spanning 4-domains subfamily A member 4A)

Beyond the preview

Go deeper on AL014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AL014.

Explore the full profile